News Search Results
Jun 04, 2025, 18:01 ET ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
with no treatment-related serious infections or discontinuations. Infections were the most common AEs; the study coincided with a high prevalence of COVID-19. This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. "These long-term results build confidence in zigakibart
More news about: ERA Congress
Jun 04, 2025, 18:01 ET ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
with no treatment-related serious infections or discontinuations. Infections were the most common AEs; the study coincided with a high prevalence of COVID-19. This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. "These long-term results build confidence in zigakibart
More news about: ERA Congress
Jun 04, 2025, 18:01 ET 유럽 신장학회 연례 학술대회: 장기 데이터는 IgA 신증 환자에게서 지가키바트의 지속적인 유효성과 안전성 보여줘
APRIL 경로 억제 효과를 확인해줬다. 지가키바트는 전반적으로 우수한 내약성을 보여줬다. 대부분의 부작용은 경증 또는 중등도에 그쳤고, 치료 관련 중증 감염이나 치료 중단 사례는 없었다. 감염이 가장 흔한 부작용이었다. 단, 연구 기간 중 코로나-19(COVID-19)가 크게 유행했다는 점을 고려해야 한다. 이번 연구는 IgAN에서 APRIL 표적 치료제 중 가장 긴 기간 동안 eGFR 안정화를 보인 사례이다. 배럿 교수는 "이런 장기적 임상 시험 결과는 IgAN의 유망한 핵심 치료제로서 지가키바트를 더욱 신뢰할
More news about: ERA Congress
Jun 04, 2025, 18:01 ET Congresso ERA: Dados de longo prazo mostram eficácia e segurança sustentadas do zigakibart em pacientes com nefropatia por IgA
infecções graves ou descontinuações relacionadas ao tratamento. As infecções foram os EAs mais comuns; o estudo coincidiu com uma alta prevalência de COVID-19. Esta é a duração mais longa de estabilização de eGFR relatada para um agente anti-APRIL em IgAN. "Esses resultados de longo prazo aumentam
More news about: ERA Congress
Jun 04, 2025, 18:01 ET Congrès de l'ERA : Les données à long terme montrent une efficacité et une sécurité durables de zigakibart chez les patients atteints de néphropathie à IgA
traitement ni d'arrêts de traitement. Les infections ont été les effets indésirables les plus fréquents ; l'étude a coïncidé avec une forte prévalence de COVID-19. Il s'agit de la plus longue durée de stabilisation du DFGe rapportée pour un agent anti-APRIL dans la maladie d'IgAN. « Ces résultats à long
More news about: ERA Congress
Jun 04, 2025, 18:01 ET Congreso ERA: eficacia y seguridad sostenidas de zigakibart en pacientes con nefropatía IgA
relacionadas con el tratamiento ni interrupciones del mismo. Las infecciones fueron los EA más frecuentes; el estudio coincidió con una alta prevalencia de COVID-19. Se trata de la estabilización de eGFR de mayor duración notificada para un agente anti-APRIL en IgAN. "Estos resultados a largo plazo refuerzan
More news about: ERA Congress
Jun 04, 2025, 18:01 ET Congreso ERA: Los datos a largo plazo muestran la eficacia y seguridad sostenidas de zigakibart en pacientes con nefropatía por IgA
graves relacionadas con el tratamiento o interrupciones. Las infecciones fueron los AA más comunes; el estudio coincidió con una alta prevalencia de COVID-19. Esta es la duración más larga de la estabilización de eGFR informada para un agente anti-ABRIL en IgAN. "Estos resultados a largo plazo generan
More news about: ERA Congress
Jun 04, 2025, 16:59 ET Dynavax Comments on Glass Lewis Recommendation
of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.
More news about: Dynavax Technologies
Jun 04, 2025, 15:06 ET Global Colorectal Cancer Screening and Diagnostics Market to Reach $46.1 Billion by 2029
disorders. Technological advancements, such as AI integration in diagnostic tools, have improved the accuracy and accessibility of screenings. The COVID-19 pandemic has highlighted the importance of regular health check-ups, further boosting the market. Additionally, the incorporation of screenings into
More news about: BCC Research LLC
Jun 04, 2025, 09:30 ET Genomma Lab successfully issued the LAB 25 and LAB 25-2 unsecured bonds (Cebures) for a total amount of $1.2 billion pesos, which will be used to prepay liabilities, including the full early amortization of the LAB 23 bond
forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays,
More news about: Genomma Lab Internacional, S.A.B. de C.V.
Jun 04, 2025, 08:42 ET Mindset Medical Announces FDA Clearance for its Contactless Respiratory Rate Measurement Device
in clinical and outpatient facilities, remote care environments, long-term care settings, or the patient's home. Telemedicine skyrocketed due to COVID-19, as many barriers to adoption were removed, allowing video conferencing to become routine. "Video alone is not enough. Patients
More news about: Mindset Medical, Inc.
Jun 04, 2025, 08:30 ET Perrigo Announces Global Operations and Supply Chain Leadership Transition
Reinvention program, which significantly reduced portfolio complexity and improved forecast accuracy. His leadership was especially impactful during the COVID-19 pandemic, when Perrigo's global facilities remained operational, ensuring continued supply of essential self-care products to consumers and customers.
More news about: Perrigo Company plc
Jun 04, 2025, 05:00 ET Ein Schritt nach vorn für Privatkunden: Eurelectrics 5 Verpflichtungen zur Unterstützung beim Übergang zu sauberer Energie
Millionen Privatkunden mit erschwinglichen, transparenten und benutzerfreundlichen Lösungen zu stärken. Um sich an eine neue Realität – geprägt durch COVID-19, den Krieg in der Ukraine und steigende Energiepreise – anzupassen, beauftragte Eurelectric eine
More news about: Eurelectric
Jun 04, 2025, 05:00 ET Stepping up for residential customers: Eurelectric's 5 commitments to support them in the energy transition
pledged to empower 300 million residential consumers with affordable, transparent, and user-friendly solutions. To adapt to a new reality shaped by COVID-19, war in Ukraine and rising energy costs, Eurelectric commissioned a
More news about: Eurelectric
Jun 04, 2025, 05:00 ET Stepping up for residential customers: Eurelectric's 5 commitments to support them in the energy transition
pledged to empower 300 million residential consumers with affordable, transparent, and user-friendly solutions. To adapt to a new reality shaped by COVID-19, war in Ukraine and rising energy costs, Eurelectric commissioned a
More news about: Eurelectric
Jun 04, 2025, 05:00 ET Comprometidos con los clientes residenciales: Los 5 compromisos del sector eléctrico
millones de consumidores residenciales con soluciones accesibles, transparentes y fáciles de usar. Para adaptarse a una nueva realidad marcada por la COVID-19, la guerra en Ucrania y el aumento de los costos energéticos, Eurelectric encargó una
More news about: Eurelectric
Jun 04, 2025, 05:00 ET Agire per i clienti residenziali: le 5 misure di Eurelectric per supportarli nella transizione energetica
fornire soluzioni accessibili, trasparenti e semplici a 300 milioni di consumatori residenziali. Per adattarsi a una realtà mutata dalla pandemia di COVID-19, dalla guerra in Ucraina e dall'aumento dei costi energetici, Eurelectric ha commissionato un
More news about: Eurelectric
Jun 04, 2025, 05:00 ET Soutenir les clients résidentiels : les 5 engagements d'Eurelectric pour les accompagner dans la transition énergétique
résidentiels en leur proposant des solutions abordables, transparentes et faciles d'utilisation. Pour s'adapter à une réalité bouleversée par la pandémie de COVID-19, la guerre en Ukraine et la hausse des coûts de l'énergie, Eurelectric a commandé une
More news about: Eurelectric
Jun 03, 2025, 16:10 ET QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics
platform can report positive results in approximately six minutes with a single multiplex test for the detection and differentiation of Flu A, Flu B and COVID-19, while negative results can be reported in approximately 10 minutes.1 The LEX Diagnostics system integrates into point-of-care workflows,
More news about: QuidelOrtho Corporation
Jun 03, 2025, 10:45 ET Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
infections in 1% of patients. Overall, 5% (13/285) of patients had Grade 5 infections, 2.5% of which were due to COVID-19. Patients treated with CARVYKTI® had an increased rate of fatal COVID-19 infections compared to the standard therapy arm. Monitor patients for signs and symptoms of infection
More news about: Johnson & Johnson
Jun 03, 2025, 10:45 ET DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
0.35–0.74). Overall survival (OS) numerically favored D-VRd (HR 0.66; 95 percent CI, 0.42–1.03), with an even greater benefit observed after censoring for COVID-19-related deaths (HR 0.55; 95 percent CI, 0.34–0.90).2 Additional data presented at ASCO included a subgroup analysis of the CEPHEUS
More news about: Johnson & Johnson
Jun 03, 2025, 08:03 ET Kindo AI Appoints Veteran Revenue Leader Mathew Varghese as Chief Revenue Officer
scaling the region from early-stage customer wins to tens of millions in annual recurring revenue (ARR), while navigating global uncertainty during the COVID-19 pandemic. Under Varghese's leadership, Silverfort's presence in the Americas matured from scrappy startup to a trusted identity security partner for
More news about: Kindo
Jun 03, 2025, 08:00 ET Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
appetite, vomiting, dizziness, COVID-19, headache, abdominal pain, hemorrhage, urinary tract infection, cough, insomnia, increased bilirubin, weight decreased, arrhythmia, fall, and pyrexia. Serious adverse reactions reported in >2% of patients included COVID-19 (7%), anemia (4.4%), pneumonia
More news about: Johnson & Johnson
Jun 02, 2025, 13:25 ET Freenome Announces JAMA Publication of Data from Pivotal Study of its Blood-Based Test for Colorectal Cancer
screening colonoscopy. Freenome and the U.S. Food and Drug Administration agreed upon a predetermined cut-off date for the period most affected by the COVID-19 pandemic. The study analyzed the 27,010 participants who enrolled consecutively or after the predetermined cut-off date. The study leveraged
More news about: Freenome Holdings, Inc.
Jun 02, 2025, 13:12 ET Else Nutrition Reports 2024 Fiscal Year Financial Results and Provides Business Update
statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID-19 and that the manufacturing, broker, and supply logistic agreement with the company does not terminate. Actual results may differ from the estimates,
More news about: Else Nutrition Holdings Inc.